You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a tele-mentoring system integrated into an ultra-portable surgical microscope to treat cataract in underserved populations

    SBC: X-BIOMEDICAL INC            Topic: NEI

    Currently, in austere environments like the rural regions of Africa, there are millions of people who go blind each year due to cataract. This is an easily preventable condition if they receive the correct treatment in a timely manner. Unfortunately, there is a growing shortage of ophthalmologists and other surgeons throughout the world, and in many African countries unsupervised non-physicians pe ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Pharmaceutical development of longer-lasting brimonidine eye drops

    SBC: Novus Vision LLC            Topic: NEI

    PROJECT SUMMARY Glaucoma is the leading cause of irreversible blindness, impacting 80 million people worldwide. The only proven approach to prevent vision loss in glaucoma is the reduction of intraocular pressure (IOP), which is most commonly achieved by topical medications. Once daily (QD) prostaglandins are a typical first-line therapy, though the need for adjunctive therapy with other drug clas ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD

    SBC: CREATIVE BIO-PEPTIDES INC            Topic: NIA

    7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Oscillated Insertion tool to Eliminate Surgically Induced Neurodegeneration for Optical Neuroimaging of Cognitive Aging and Dementia

    SBC: ACTUATED MEDICAL, INC.            Topic: NIA

    This Phase I SBIR develops a system for gentle and accurate insertion of large optical neuroscience probes (e.g., GRIN lenses) to improve outcomes in aging research. Additionally, the project supports Qingguang Zhang. Ph.D. through the NIA Research and Entrepreneurial Development Immersion (REDI) program at a small business. Entrepreneurial development activities for his project will include proje ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Ultrasound Stimulated Chondrogenic Stem Cell Therapy for Osteoarthritis

    SBC: LAB TO PHARMACY, LLC            Topic: NIAMS

    Abstract Osteoarthritis (OA) is the most common degenerative disease in the musculoskeletal system. While it can affect any joint, hip, and knee, OA carries an enormous burden of pain and reduced mobility. Despite decades of research, there are currently no clinically effective treatments that can repair damaged cartilage or halt the progression of this disease. However, recent advances in tissue ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.

    SBC: PREVEP, LLC            Topic: NINDS

    Abstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Patient-Facing Portal for the Receipt, Interpretation and Tracking Utility of Pharmacogenetic (PGx) Data

    SBC: GENOMIND INC            Topic: 172

    ABSTRACT Selection of medication for mental illness is generally through trial-and-error, with high rates of adverse reactions and sub-optimal efficacy. Pharmacogenetic (PGx) data is thus of particular benefit to facilitate selection of safe and effective medications and is cost effective, decreases resource utilization, and improves patient engagement, with the potential to overcome medication no ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Synergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC

    SBC: CREEGH PHARMACEUTICALS INC            Topic: NCI

    15-20% of all breast cancers are triple negative, being devoid of the three receptors that classify and define treatment strategies for most mammary cancers: estrogen receptor (ER), progesterone receptor (PR) and ERB2 (also known as HER2). Because of this, no targeted therapies are available for TNBC patients. This poses a destitute situation, as TNBC is an aggressive cancer that disproportionally ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief

    SBC: VANISH THERAPEUTICS INC            Topic: NINDS

    Project Summary The lack of effective pain treatments has catalyzed the opioid epidemic in America, causing an estimated 93,000 deaths in 2020, calling for more effective and non-opioid based management. One alternative pain treatment is via nerve stimulators, which are devices placed near a peripheral nerve or on the spinal cord and use electrical signals to modulate the perception of pain. Most ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government